Cephalosporin derivatives

• US 5,407,930 A
• Filed: 03/24/1994
• Issued: 04/18/1995
• Est. Priority Date: 03/20/1986
• Status: Expired due to Fees

• Current Assignee: Banyu Pharmaceutical Company Limited (Merck & Co., Inc.)
• Original Assignee: Banyu Pharmaceutical Company Limited (Merck & Co., Inc.)
• Inventors: Asai, Akira, Nakagawa, Susumu, Ushijima, Ryosuke, Mitomo, Ryuji, Kuroyanagi, Satoru
• Primary Examiner(s): Rizzo, Nicholas
• Application Number:
  US08/217,023
• Time in Patent Office: 390 Days
• Field of Search: 514/206, 540/227, 540/226
• US Class Current: 514/206
• CPC Class Codes: C07D 501/00 Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula: , e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Abstract

The present invention relates to a compound represented by the structural formula I: ##STR1## its pharmaceutically acceptable salt or ester, or its crystalline, which is a novel optically active compound useful as a curing agent for bacterial infections, a process for production thereof and a use thereof.

Claims

1. A crystalline optically active compound of S-configuration of the structural formula I:

##STR11## or its pharmaceutically acceptable salt or ester.

2. The optionally active compound according to claim 1, wherein its X-ray diffraction pattern is:

space="preserve" listing-type="tabular">______________________________________ d I/Imax (%) ______________________________________ 34.6865 8.31 12.3019 19.49 8.6232 27.30 8.2423 22.80 7.1902 8.31 5.8937 48.12 5.8176 51.94 5.3131 26.37 5.1513 20.29 4.5976 17.93 4.4158 44.44 4.2510 18.70 4.0580 39.77 3.9269 9.94 3.7348 100.00 3.4606 45.65 3.2964 35.35 3.0574 9.94 2.9025 16.44 2.8533 11.11 2.6699 27.30 2.6112 15.01 2.5393 15.71 2.4356 22.80 ______________________________________

3. A crystalline optically active compound of S-configuration which is 7-[(Z)-2-(2-aminothiazol-4-yl)-2-[[(S)-α

-carboxy-3,4-dihydroxybenzyl]oxyimino]acetamido]-3-[(1-carboxylatomethyl-4-pyridinio)thiomethyl]-3-cephem-4-carboxylic acid, its pharmaceutically acceptable salt or ester, or its solvate.

4. The compound according to claim 3, which is a crystalline formic acid solvate.

5. The compound according to claim 3, which is a crystalline hydrate.

6. An antibacterial composition comprising an effective amount of the compound of claim 3 in admixture with a pharmaceutically acceptable, non-toxic carrier or excipient.

7. A method for the treatment of an infectious disease in a subject needing such treatment, which comprises administering an effective amount of the compound of claim 3 to the subject.